State Lawmakers Call For FTC To Probe CVS Caremark

By Brendan Pierson

Law360, New York (May 07, 2009, 12:00 AM ET) -- A group of state lawmakers has asked the Federal Trade Commission to investigate whether the 2007 merger that created CVS Caremark Corp. has led to fraudulent and anti-competitive conduct, hurting prescription drug consumers.

Sharon Anglin Treat, executive director of the National Legislative Association on Prescription Drug Prices, said in a letter to FTC Chairman Jon Leibowitz on Thursday that the combination of CVS, a pharmacy operator, and Caremark, a pharmacy benefit manager, created opportunities for the company to enrich itself at the expense of competition and...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles